Acc 23: Evaluation Of The Mechanism Of Benefit For Dapagliflozin In Hfpef

ACC 23: Evaluation of the Mechanism of Benefit for Dapagliflozin in HFpEF

Best Practices for Starting SGLT2 Inhibitors in HFpEF Treatment

HF 2022: DELIVER Extends Benefits of Dapagliflozin to the Full Spectrum of Pts with HF

HFA 23: DAPA MODA: Dapaglifozin & Cardiac Remodelling in Chronic HF

Further research studies of Dapagliflozin

Cardiomyopathy UK

HFA 23: DAPA-HF and DELIVER: KCCQ in Patients with Varying Ejection Fraction

SGLT2 Inhibitors and Heart Failure

Harvard Medical School Continuing Education

CAMEO-DAPA Trial: Effects of Dapagliflozin on Invasive Hemodynamics in HFpEF | Dr. Barry Borlaug

HFA 23: The DELIVER Phase III Trial

Nurse Webinars - Dapagliflozin and Heart Failure

Cardiomyopathy UK

ACC HFpEF Guidance What to Know

PRESERVED-HF: Support for dapagliflozin to improve HFpEF health status | Mikhail Kosiborod

Medicine Matters diabetes

ESC 23 Late-Breaker Discussion: The STEP HFpEF Trial

Dapagliflozin for heart failure: a pooled analysis of DAPA-HF and DELIVER

ACC 23 Interventional Late-breaking Highlights with Dr Mirvat Alasnag & Dr Khaled Al-Shaibi

ACC 23: BMAD Trial: μCor in Ambulatory Decompensated Heart Failure

ESC Highlights #heart #medicine #heartfailure #obesity #semaglutide #HFpEF

LBCT Dapagliflozin and Atrial Fibrillation in HFpEF in DELIVER | ESC Congress 2022

American College of Cardiology